Corvus Pharmaceuticals, Inc.
No SEC Form 4 filings for $CRVS in the last 30 days.
See all $CRVS insider activity →Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.
Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopi
Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (
Over the past 7 days, alphai's AI scored 2 news stories mentioning CRVS (Corvus Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CRVS coverage spans financial news, earnings and corporate actions.
Near-term trading focus shifts to PTCL trial decision timing (interim futility in Q1 2027) and ongoing atopic dermatitis enrollment/data milestones.
The filing is a near-term catalyst for CRVS risk pricing via updated trial progress and a materially larger cash balance extending funding runway.
Board turnover can affect governance, committee leadership, and investor sentiment, but the filing provides no operational or financial details.
The Form 4 insider buy is a modest bullish signal, but the stake size is tiny and options vesting is delayed.
A director open-market buy is a modest bullish signal, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions CRVS with an AI model for sentiment and relevance, and aggregates insider trades from Corvus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.
6 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopi
5 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Corvus Pharmaceuticals, Inc._July 21, 2026 0001626971 false 0001626971 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (
1 min readCorvus Pharmaceuticals said director David Scott Moore bought 21,700 common shares on June 11, 2026 via option exercise, according to a June 15 SEC Form 4. The weighted average purchase price was $11.53, with a $11.60 close price. Moore also holds 15,000 options at $11.60 that won’t vest until about a year later.
4 min readMoore David Scott purchased 21,700 shares of Corvus Pharmaceuticals, Inc. (CRVS) at $11.53 ($0.25M total) on 2026-06-11.
2 min readCorvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readWall Street Zen has upgraded Corvus Pharmaceuticals (NASDAQ:CRVS) from a "sell" to a "hold" rating. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $33.33. Despite missing quarterly earnings estimates, institutional investors have increased their stakes in the biopharmaceutical company.
3 min readCorvus Pharmaceuticals reported zero revenue and a net loss of $15.283 million, despite $27.141 million in non-operating income from warrant fair value changes. The operating loss widened to $(42.971) million due to increased R&D spending to advance soquelitinib into Phase 3 and Phase 2 trials. A January 2026 follow-on offering raised approximately $189 million, extending the company’s cash runway into the second quarter of 2028.
2 min readCorvus Pharmaceuticals Inc. (CRVS) reported a fourth-quarter loss of $12.3 million, or 15 cents per share. For the entire year, the company's loss totaled $15.3 million, equating to 53 cents per share. This financial data was generated with information from Zacks Investment Research.
2 min readCorvus Pharmaceuticals (CRVS) saw its stock soar by 211.8% after announcing positive results from a clinical trial for its eczema therapy, soquelitinib. The drug candidate demonstrated a significant reduction in eczema severity, leading the company to plan a Phase 2 trial for early 2026. Despite the impressive gains, the article suggests that some AI stocks might offer better prospective returns.
2 min read
